GlassScriptPhysician profile
Varuna Nargunan
NPI 1386807089
$6,032.94
in general payments reported to CMS, 2019-2025
39 companies · $1,008 in 2025
The $1,008 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2020: $875 · 2021: $949 · 2022: $875 · 2023: $653 · 2024: $904 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503 · Education: $62.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.00 |
| Education | $62.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $883.80 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Astrazeneca Pharmaceuticals LP | $802.06 | 2019-2022 | |
| Lilly USA, LLC | $765.60 | 2019-2025 | Mounjaro, Zepbound, Humulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.94 | 2019-2025 | Jardiance, Synjardy |
| Amgen INC. | $643.03 | 2019-2025 | Tepezza, Repatha, Repatha |
| Abbott Laboratories | $307.23 | 2021-2025 | Freestyle Libre 3, Proclaim, Absolute Pro |
| Insulet Corporation | $275.58 | 2022-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $233.01 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $208.32 | 2021-2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $161.42 | 2022-2025 | |
| Horizon Therapeutics Plc | $132.30 | 2023 | Tepezza |
| Tandem Diabetes Care, INC. | $111.83 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $83.87 | 2020-2024 | Veozah |
| Mannkind Corporation | $82.27 | 2023-2025 | Afrezza |
| Dexcom, INC. | $67.54 | 2019-2025 | Dexcom G6 Transmitter |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varuna Nargunan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.